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Abstract
Background: To realize the promise of personalized medicine, diagnostic instruments used for detecting and
measuring biomarkers must become smaller, faster and less expensive. Although most techniques used currently to
detect biomarkers are sensitive and specific, many suffer from several disadvantages including their complexity,
high cost and long turnaround time. One strategy to overcome these problems is to exploit carbon nanotube
(CNT) based biosensors, which are sensitive, use inexpensive disposable components and can be easily adapted to
current assay protocols. In this study we investigated the applicability of using a CNT field-effect transistor (CNT-
FET) as a diagnostic instrument for measuring cancer biomarkers in serum using a mouse model of Breast Cancer
Susceptibility 1-related breast cancer. Insulin like growth factor-1 (IGF-1) was chosen because it is highly relevant in
breast cancer and because measuring serum IGF-1 levels by conventional methods is complicated due to specific
IGF-1 serum binding proteins.
Findings: Our results show that there is good correlation between the two platforms with respect to detecting
serum IGF-1. In fact, the CNT-FETs required only one antibody, gave real-time results and required approximately
100-fold less mouse serum than the radioimmunoassay.
Conclusions: Both IGF-1 radioimmuno and CNT-FET assays gave comparable results. Indeed, the CNT-FET assay
was simpler and faster than the radioimmunoassay. Additionally, the low serum sample required by CNT-FETs can
be especially advantageous for studies constricted by limited amount of human clinical samples and for mouse
studies, since animals often need to be sacrificed to obtain enough serum for biomarker evaluation.
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Findings
Insulin-like growth factor-1 (IGF-1) is a pleiotropic 70
amino acid peptide produced mainly by the liver. It is a
potent mitogen and survival factor for many cell types
including smooth muscle, epithelial and interstitial cells
and is vital for normal development and cell differentia-
tion. Conversely, it also has a role in abnormal physiology
such as mammary carcinogenesis and tumor growth [1].
Circulating levels of IGF-1 are positively associated with
increased breast cancer risk in pre- and postmenopausal
women, particularly for estrogen-receptor positive
tumors [2-4]. Moreover, the IGF-1/IGF-1 receptor axis
has also been shown to be involved in the increased risk
of early-onset breast cancers in women with mutations in
the Breast Cancer Susceptibility gene (BRCA1). [5-7].
Germline mutations in BRCA1 have been detected in
approximately half of human familial breast cancer cases
[8,9].
In order to gain insights into the downstream factors
involved in human BRCA1-associated breast cancers, a
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mouse model was developed with a conditional Brca1
gene deletion [10]. This mouse model demonstrates a
pattern of progressive adenocarcinoma with similar
genetic changes and pathophysiology as seen in human
breast cancers associated with BRCA1-mutations
[11,12]. Additionally, as in human BRCA1-associated
breast cancer, increased expression of several compo-
nents of the IGF axis is seen in liver, normal mammary
tissue and mammary tumors of these mice along with
increased levels of IGF-1 in serum [13].
Currently, breast self-exams and mammograms are the
predominant methods used to detect breast cancer in its
early stages. Unfortunately, blood tests for breast cancer
biomarkers are not yet a routine diagnostic procedure as
for many other cancers, but many studies have shown that
IGFs, IGF binding proteins (IGFBPs) and IGF receptors
are good candidates for breast cancer markers because
they are strong prognostic factors for breast cancer out-
comes [4,14-16]. Because of the need for fast and inexpen-
sive diagnostic tools to detect risk factors associated with
breast cancers and other malignancies, we investigated the
possibility of using a carbon nanotube field-effect transis-
tor (CNT-FET) to measure serum IGF-1 levels in the
Brca1-associated mouse model of human breast cancer.
This assay was compared to a radioimmunoassay (RIA)
method that is performed by clinical laboratories.
CNTs are two-dimensional graphene sheets forged into
elongated tubes which display unique physical attributes,
such as high tensile strength and excellent electrical con-
ductivity, which makes them attractive for use in nano-
scale biodetectors. Additionally, CNT-based biodetectors
are versatile and can use either antibody, aptamer or avi-
din-biotin based capture [17-23]. The CNT-FET wafer
design used in this study is shown in Figure 1 and was
developed by Fuzbien Technology Institute (FTI, Rock-
ville, MD). It is a semiconductor element that has three
terminals; a source, drain and gate electrode, which is a
configuration similar to that of conventional silicon
metal-oxide-semiconductor field-effect transistors
(MOS-FET). The wafer has 92 independent CNT-FET
circuits that can handle sample volumes between 1-5 μl.
The CNT-FET assay procedure is similar to immunode-
tection methods, such as an Enzyme-Linked Immunosor-
bent Assay (ELISA), in that an immobilized antibody is
first used to capture the ligand. Unlike ELISA, which
requires a labeled secondary antibody to generate a
detectable signal, the CNT-FET detects the electrical
properties of the bound ligand. When a charged ligand is
in close proximity to a CNT carrying a current, the impe-
dance (resistance) either increases or decreases. This
change in impedance upon IGF-1 binding to the immobi-
lized anti-IGF-1 antibody happens in real time. The
impedance from the CNT-FET wafer is fed to a laptop
containing a data acquisition program, which display the
results with resolution down to 10-10 Amp and resistance
up to 109 Ohm.
Using a sandwich ELISA format to measure serum
IGF-1 presents a problem because more than 95% of
IGF-1 in circulation is present in high molecular weight
complexes, mostly with IGFBP-3 [17]. There are six
IGFBPs in circulation that can bind IGFs with high affinity
and interfere with antibody-based detection, especially
when a 2 antibody sandwich format is used. Therefore the
IGF-1 RIA kit used in this study includes a denaturing
step to dissociate the IGF-1: IGFBP-3 complex. First, a
mild denaturing step employing a low pH buffer is used to
dissociate the IGF-1-IGFBP complex. Then the serum
sample is returned to physiological pH in the presence of
excess IGF-2 provided in the kit. The excess IGF-2 satu-
rates the refolded IGFBPs present in the sample, leaving
the IGF-1 free to bind the antibodies. In contrast, the
CNT-FET required only one antibody and no pre-treat-
ment of the serum sample was needed. Since the CNT-
FET is only sensitive to the electrical properties of a
bound antigen, denaturing and dissociating a specific pro-
tein-antigen complex is not required to achieve a signal.
Additionally, the CNT-FET assays used 2-5 μl of 1:10-1:50
diluted mouse serum per circuit, whereas the RIA required
at least 50-100 μl of undiluted mouse serum.
Both the RIA and CNT-FET assay gave comparable
results using the same mouse plasma samples, namely a
statistically significant increase in serum IGF-1 from
Brca1f/f; MMTV-Cre mice between 3 to 6 months of age with
no further increase between 6-12 months (Figure 2, panels
A and B). No significant difference in IGF-1 serum levels
were seen in age matched CL57Bl/6 mice (data not
shown). These data complement the studies of Shukla et
al [13] that show an increase in serum IGF-1 levels after 3
months in a mouse model that is p53+/- and Brca1 f/f;
MMTV-Cre, compared to normal CL57Bl/6 controls [13].
But at this point it is unclear whether alterations in Brca1,
p53, or both are responsible for the increased IGF-1 levels.
Another possible explanation of why we did not see a
further increase in IGF-1 serum levels beyond 6 months of
age is that none of those Brca1f/f; MMTV-Cre mice at that
age developed mammary tumors.
We anticipate that CNT-based biosensors will ulti-
mately provide a rapid clinical tool to accurately and
inexpensively help define the therapeutic potential of
candidate biomarkers, such as IGF-1 for the early detec-
tion of breast cancer. These studies are important since
the breast cancers from populations of women at high
risk have elevated levels of circulating IGF-1 (e.g. women
with BRCA1 mutations) are more difficult to treat/man-
age due to their aggressive nature and because the
patients are often not candidates for standard endocrine
therapy [24-26]. Furthermore, the low sample volumes
used for the CNT-FETs means that a small blood sample
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can be used to screen for multiple biomarkers. A stan-
dard 8 ml vacutainer can yield enough serum for
approximately 5000 measurements. Apart from making
blood testing faster and more accessible, the low volume
used by the CNT-FETs can be especially important
where sample volumes are limited as in the case of blood
from premature infants, biopsy samples from cancer
patients and cerebrospinal fluid from patients suffering
from neurodegenerative diseases such as Alzheimer’s and
Parkinson disease.
Transgenic Mice and Sample Preparation
Brca1 conditional knockout mice with two floxed Brca1
alleles (Brca1f/f) carrying the mouse mammary tumor
virus (MMTV)-Cre recombinase gene (Brca1f/f; MMTV-Cre)
were maintained on a C57Bl/6 genetic background [10].
These mice continue to express the normal splice variant
of Brca1 that lacks exon 11 and develop chromosome
abnormality and tumorigenesis at low frequency after a
long period [10,11]. Specifically, approximately 25% of
mice develop mammary adenocarcinomas by 12 month of
age when both p53 alleles are intact but is increased signif-
icantly (37-80%) by p53 haploinsufficiency [10,11]. The
presence of the floxed Brca1 alleles, of wild-type Brca1
alleles, and of MMTV-Cre was identified by performing
DNA polymerase chain reactions (PCR) on tail bleeds
using primers described previously [27,10]. The transgenic
mice and wild type C57Bl/6 mice were maintained in
Figure 1 Current Fuzbien Technology Institute (FTI) CNT-FET. Each 4’’ silica semiconductor wafer has forty six 0.45’’x 0.15’’cells containing 2
independent CNT circuits (upper and lower). An enlarged view of a cell indicating the contact surfaces of the source and the drain is shown to
the right of the wafer. Gate voltage is applied at the back of the wafer. Also indicated are the aligning markers for the lithography printing
system. Below the cell is a SEM of a circuit showing the CNT’s sandwiched between the gold source and drain electrodes.
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temperature-controlled and light-controlled conditions in
the University of Maryland, Baltimore animal facility and
maintained in accordance with institutional guidelines
approved by the University of Maryland, Baltimore Animal
Care and Use Committee. To compare RIA and CNT-FET
assays, Brca1f/f; MMTV-Cre mice and wild type C57Bl/6 mice
were euthanized at 3, 6 and 12 months of age to collect
trunk blood. For histology, mammary tissue from 3, 6 and
12 month old mice was removed post mortem and forma-
lin fixed for histology and stained with hematoxylin and
eosin.
IGF-1 Radioimmunoassay
Three to five female mice were used per group. Mouse
IGF-I serum levels were measured using a RIA kit contain-
ing microplates coated with the capture antibody and a
I125 labeled detector antibody (Alpco Diagnostic, Salem,
NH). The assay was performed according to manufac-
turer’s instructions. Statistical differences among groups
were analyzed using GraphPad Prism t tests (GraphPad
Software, San Diego, CA). Data are presented as means ±
S.E.M. Significance was assigned at P ≤ 0.05.
IGF-1 CNT-FET Assay
Single-walled carbon nanotubes (SWNTs) were pur-
chased from Carbon Nanotechnologies Inc. The SWNTs
mixture used contains about 70% conducting nanotubes
that have diameters between 0.7 to 1.4 nm and length
between 20 to 80 nm. 92 sample-well CNT wafers were
manufactured by NanoPlatform Inc., using standard
photolithography and lift-off process. CNT’s were then
functionalized with pyrene butanoic acid succinimidyl
ester as previously described [28]. An anti mouse IGF-1
was purchased from Abcam and diluted in PBS to 20 μg/
ml. 5 μl of the antibody dilution was added to each CNT-
FET circuit and incubated for 1 hr at RT followed by
blocking with 0.001% BSA, washing with diH2O and dry-
ing with N2 gas. For the assays, a baseline impedance
value for the circuit was obtained using PBS for 30 sec,
after which 5 μl of purified recombinant mouse IGF-1
(eBioscience), diluted from 1-1000 ng/ml in PBS or
mouse serum, diluted 1:10-1:50 in PBS, were added to
the CNT-FET and change in impedance was measured
for 3 min. The impedance value for each IGF-1 measure-
ment was normalized to the corresponding PBS baseline
value. Each sample was measured at least in quadrupli-
cate using a fresh circuit for each measurement. A
source/drain bias of 100 mV was maintained throughout
the measurements of the electrical signal and the pulse
width was 1 sec. The reference electrode is the back (bot-
tom) side of the grounded wafer. A schematic of the
experimental setup of the assay is depicted in Figure 3,
panel A. The device uniformity was not optimized for
entire wafers, but individual circuits used for the assays
were carefully evaluated before the experiment. The
selected CNT-FET circuits ranged typically between five
and ten in on/off ratio. The electrical properties of the
samples binding the CNT-FET were measured using a
low current measurement system (LCM) by MediSource-
Plus Inc. that makes electrical contact to the source and
Figure 2 Measurement of IGF-1 in mouse serum. Mouse serum IGF-1 was measured using (A) radioimmuno assay and (B) CNT-FET. The
impedance value for each IGF-1 measurement was normalized to the corresponding PBS baseline value. Both assays show an increase in the
serum IGF-1 at 6 months compared to 3 months. Between After 6 and 12 months there is not a significant difference in the IGF levels between
the age groups. Statistical differences among groups were analyzed using GraphPad Prism t tests (GraphPad Software, San Diego, CA). The
values represent the average of ≥ 4 measurements ± standard error of the mean (SEM). Significance of P ≤ 0.05 is indicated with an asterisk.
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drain electrodes of the CNT-FET. The transfer character-
istics of this circuit design were previously characterized
for detection of prostate specific antigen [28]. Briefly,
typical observed electronic transfer changes from 20 to
10 nano amperes before and after the antibody immobili-
zation on the CNT-FET circuits when Vds and VG are 0.1
and -0.1 volt, respectively. With the IGF introduced on
the circuit, the response in the electrical signal is typically
in the range of 2 to 15% in the normalized units. A
response of IGF-1 binding to the anti-IGF-1 antibody
immobilized on our CNT-FET is shown in Figure 3B.
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